Currently, the guidelines suggest the use of ICIs with anti-PD1, in association or not with anti-CTLA4, in patients with metastatic melanoma, regardless of BRAF status, allowing long-lasting responses and long-time survival in the responders [51,52]. The gene discussed is BRAF; the disease is metastatic melanoma.